This question tests management of lithium toxicity from drug interactions. The patient's polyuria, polydipsia, tremor, elevated lithium level, and increased creatinine after starting ibuprofen indicates lithium toxicity, as NSAIDs reduce renal lithium clearance by inhibiting prostaglandin synthesis. The correct answer (B) appropriately holds lithium, recommends urgent evaluation, avoids NSAIDs, and ensures proper monitoring. Option A dangerously continues both drugs and restricts fluids which could worsen toxicity. Option C incorrectly blames quetiapine which doesn't significantly affect lithium levels. Option D shows dangerous misunderstanding by increasing lithium dose. NSAIDs can increase lithium levels by 20-60% within days; safer alternatives include acetaminophen or aspirin (with caution). When NSAIDs are necessary, reduce lithium dose prophylactically by 20-25% and monitor levels within 4-5 days.

This question tests the recognition of lithium toxicity from drug interactions affecting renal clearance. The key patient-specific factor is the recent addition of hydrochlorothiazide, which reduces lithium excretion leading to elevated levels (1.9 mEq/L) and symptoms like tremor, nausea, and slurred speech. Option B is the best choice because it identifies hydrochlorothiazide as the cause of lithium toxicity, requiring discontinuation or dose adjustment of lithium with monitoring. Option A is incorrect as quetiapine does not inhibit CYP3A4 or elevate lithium, option C is wrong because lithium does not cause anaphylaxis, and option D is suboptimal as hydrochlorothiazide does not induce serotonin syndrome. A clinical pearl is that thiazides can increase lithium levels by 25-40% via sodium depletion and reduced clearance. A decision framework for lithium therapy involves monitoring levels (target 0.6-1.2 mEq/L) with any diuretic or NSAID addition, holding doses if toxic, and ensuring hydration to prevent recurrence.

This question tests the management of spironolactone-induced gynecomastia in heart failure patients. The key patient-specific factor is the development of gynecomastia and breast tenderness after months on spironolactone, due to its anti-androgenic effects in a male patient with heart failure. Option B is the best choice because switching to eplerenone, a selective aldosterone antagonist, maintains heart failure benefits while reducing endocrine side effects like gynecomastia, with monitoring for hyperkalemia. Option A is incorrect as ACE inhibitors like lisinopril do not cause gynecomastia, and option C is wrong because adding testosterone is not standard and may have risks. Option D is suboptimal as increasing spironolactone would worsen symptoms. A clinical pearl is that spironolactone causes gynecomastia in up to 10% of men due to estrogenic activity, whereas eplerenone has lower incidence. In heart failure therapy, if endocrine effects occur, switch to eplerenone while ensuring potassium and renal monitoring to balance efficacy and tolerability.

This question tests counseling to prevent disulfiram-like reactions from metronidazole-alcohol interactions. The key patient-specific factor is the patient's consumption of wine while on metronidazole, leading to flushing, headache, palpitations, and vomiting due to aldehyde dehydrogenase inhibition. Option A is the best choice because avoiding alcohol during and for 3 days after metronidazole therapy prevents the reaction, aligning with standard guidelines. Option B is incorrect as increasing alcohol builds no tolerance and risks severity, while option C is wrong because grapefruit juice does not mitigate flushing. Option D is suboptimal as oral contraceptives are unrelated to this reaction. A clinical pearl is that metronidazole can cause disulfiram-like effects even with small alcohol amounts, lasting up to 4 days post-therapy. In antimicrobial counseling, always screen for alcohol use and advise abstinence, using frameworks like educating on symptom recognition and duration to enhance adherence and safety.

This question tests management of warfarin-drug interactions causing supratherapeutic INR. The patient's INR of 6.8 with bleeding symptoms after starting trimethoprim-sulfamethoxazole indicates a significant drug interaction, as sulfonamides inhibit warfarin metabolism and displace it from protein binding sites. The correct answer (B) appropriately holds both medications, administers vitamin K for INR reversal, and ensures proper follow-up. Option A is dangerous as continuing both drugs could worsen bleeding, and dietary vitamin K is insufficient for acute management. Option C incorrectly blames levothyroxine which doesn't cause acute INR changes. Option D shows fundamental misunderstanding as antibiotics typically increase, not decrease, warfarin effect. When starting interacting antibiotics in warfarin patients, proactively reduce warfarin dose by 10-25% and monitor INR within 3-5 days to prevent bleeding complications.

This question tests recognition of ACE inhibitor-induced cough, a classic adverse effect. The temporal relationship of dry cough starting 3 weeks after lisinopril initiation clearly identifies it as the causative agent, occurring in 5-10% of patients due to bradykinin accumulation. The correct answer (C) identifies lisinopril as the cause. Option A (atorvastatin) rarely causes cough and the timing doesn't match. Option B (metformin) doesn't cause cough as an adverse effect. Option D suggesting GERD is incorrect as the presentation is classic for ACE inhibitor cough without reflux symptoms. ACE inhibitor cough is dry, persistent, and typically develops within 1-8 weeks of initiation; it resolves within 1-4 weeks of discontinuation. Patients requiring ACE inhibitor therapy who develop cough should be switched to an ARB, which doesn't affect bradykinin metabolism.

This question tests monitoring parameters for digoxin toxicity prevention. The patient presents with classic digoxin toxicity symptoms (nausea, anorexia, visual disturbances) with elevated level, worsening renal function, and hypokalemia - all factors that increase digoxin toxicity risk. The correct answer (A) identifies the need to monitor potassium (as hypokalemia increases digoxin binding to Na-K-ATPase) and renal function (as digoxin is renally eliminated). Option B incorrectly suggests HbA1c monitoring which is unrelated to digoxin toxicity. Option C suggests INR monitoring but digoxin doesn't significantly interact with warfarin. Option D incorrectly suggests CK monitoring as digoxin doesn't cause myopathy. Key principle: digoxin has a narrow therapeutic index requiring monitoring of levels, renal function, and potassium, with dose adjustments for declining kidney function and correction of hypokalemia to prevent toxicity.

This question tests management of opioid-induced constipation (OIC), a predictable adverse effect. The patient's constipation after 3 months of regular oxycodone use is classic OIC, occurring in up to 95% of chronic opioid users due to mu-receptor activation in the GI tract. The correct answer (B) appropriately recommends scheduled bowel regimen with stimulant laxative (for motility) plus stool softener, with potential osmotic agent escalation. Option A incorrectly blames gabapentin which rarely causes severe constipation. Option C wrongly implicates omeprazole and misunderstands the mechanism. Option D dangerously recommends loperamide (an anti-diarrheal) which would worsen constipation. Key principle: OIC requires prophylactic bowel regimens starting with opioid initiation, as tolerance doesn't develop to GI effects unlike analgesia, using scheduled rather than PRN laxatives.

This question tests the management of warfarin drug interactions, specifically with amiodarone causing supratherapeutic INR. The key patient-specific factor is the recent initiation of amiodarone, which inhibits warfarin metabolism via CYP2C9, leading to elevated INR (5.6) and minor bleeding in a stable patient. Option B is the best choice because holding 1-2 warfarin doses and reducing the maintenance dose with close INR monitoring safely addresses the interaction without overcorrecting. Option A is incorrect as the INR will not self-correct without adjustment, risking thrombosis or bleeding, and option C is wrong because stopping amiodarone abruptly could destabilize arrhythmia control, and clopidogrel is not a warfarin substitute. Option D is suboptimal as vitamin K is reserved for major bleeding or very high INRs, not routine use. A clinical pearl is that amiodarone can increase warfarin effects by 25-50%, often requiring dose reductions of 20-40%. A decision framework for warfarin interactions involves anticipating potency (e.g., amiodarone's delayed onset), holding doses if INR >4-5 without bleeding, and frequent monitoring post-change.

This question tests the recognition of drug-induced hypoglycemia from sulfonylurea interactions. The key patient-specific factor is the recent initiation of trimethoprim-sulfamethoxazole (TMP-SMX), which inhibits CYP2C9 metabolism of glyburide, leading to enhanced sulfonylurea effects and symptomatic hypoglycemia (glucose 48 mg/dL). Option A is the best choice because it correctly identifies the interaction causing hypoglycemia, requiring TMP-SMX discontinuation or glyburide adjustment. Option B is incorrect as TMP-SMX does not cause hyperglycemia, and option C is wrong because metformin lactic acidosis is rare with normal renal function. Option D is suboptimal as glyburide does not cause diabetic ketoacidosis. A clinical pearl is that sulfonylureas like glyburide have higher hypoglycemia risk in the elderly or with CYP inhibitors like TMP-SMX. A decision framework for hypoglycemia involves checking for drug interactions, treating acutely with glucose, and adjusting therapy to prevent recurrence.